Dupixent Commercial 2025

Dupixent Commercial 2025. The fda has accepted the resubmission of the supplemental biologics license application (sbla) for dupixent (dupilumab) to treat adults and pediatric patients aged 12. In the dupixent tv spot titled “show off:


Dupixent Commercial 2025

If approved, dupixent is expected to become the first targeted csu therapy in ten years. The commercial follows kathy and adante, who are introduced as real patients.

Dupixent Commercial 2025 Images References :